The Greater Manchester Clinical Reference Group reviewed a request to add omalizumab to formulary for the unlicensed indications of severe chronic inducible urticarias (solar urticaria, cold and heat urticaria, symptomatic dermographism, delayed pressure urticaria and cholinergic urticaria). We now seek comments on this draft
The consultation will run for 6 weeks, closing at 5pm on 29th August. To take part, please visit the consultations page.